YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Ke…
Blood test ©Adobe Stock Images Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc. have finalised an exclusive distribution and reseller agreement covering Virotek's ophthalmology genomic testing and screening programme in the United States. Und…
Blood test ©Adobe Stock Images The proposed exclusive U.S. distribution agreement would give Kala a commercial opportunity in its established ophthalmology market while leaving Virotek responsible for laboratory operations and clinical rep…
ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-bu…
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto, Ontario and Arlington, Massachusetts--…
DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with d…
(RTTNews) - Shares of Kala Bio, Inc. (KALA) jumped more than 75% in pre-market trading after the company announced it will deploy its first commercial AI agent within 14 days, marking a major shift from a single-asset biotech into a dual-e…
KALA BIO, Inc. Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to…
ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a d…
Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s cont…
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational mi…
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the…
* KALA BIO (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]) on Thursday said that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock, at $1.00 per share in a registered d…
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 127,931,595 0.0325 0.0265 0.0315 -0.0025 Ka…
Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia ar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Direct Digital Holdings Inc. 237,043,770 0.1799 0.1469 0.1501 +0.0349 Q32…
Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of persistent corneal epithelial defect (PCED)…
MoonLake Immunotherapeutics (MLTX) shares sank 90% following the release of data from its late-stage PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Closeup irritated infected red bloodshot eyes, conjunctivitis] Andrei310/iStock via Getty Images * Shares of KALA Bio (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]) have plummeted ~92% in premarket trading Monday after reporting tha…
(RTTNews) - KALA BIO Inc. (KALA) is in focus, as anticipation builds around its upcoming clinical trial data for KPI-012, a novel stem cell-derived therapy targeting persistent corneal epithelial defect or PCED, a rare and debilitating eye…
(RTTNews) - Biopharmaceutical company KALA BIO, Inc. (KALA) announced Tuesday that Todd Bazemore has been named President and Chief Executive Officer (CEO) and appointed to the Board of Directors. Bazemore has served as KALA's interim CEO…
(RTTNews) - September 2025 could be a make-or-break month for some biotech stocks, as the companies prepare to release critical clinical trial data. The following are some of the biotech stocks to watch in September, with potential catalys…
* KALA BIO press release [https://seekingalpha.com/pr/20194841-kala-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]): Q2 Non-GAAP EPS of -$1.71. * Cash re…
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fu…
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases…
For Immediate Release Chicago, IL – July 28, 2025 – Stocks in this week’s article are KALA BIO, Inc. KALA, Graham Corp. GHM, Arq, Inc. ARQ and Hawkins, Inc. HWKN. Analyst Coverage Sparks Interest in These 4 Stocks In the current backdrop o…
In the current backdrop of heightened economic uncertainty—marked by tariff volatility, inflationary pressure, and growing concerns over policy interference—new analyst coverage plays a crucial role in guiding investors through volatility.…
Kala Bio, Inc. (NASDAQ:KALA), a small-cap biotech with a market capitalization of $33.29 million, announced Wednesday the completion of patient enrollment in its CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem ce…
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., Ju…
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases o…
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases…
KALA BIO, Inc. ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended an…
KALA BIO, Inc. -- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining fun…
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM…
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 201…